Login to Your Account



Assay What? Tysabri's PML Woes Could Find Partial Fix

By Randy Osborne


Monday, April 12, 2010
Some of the world's best scientific brains were gearing up for the American Academy of Neurology meeting this week in Toronto, and among the hoped-for data to tumble out of sessions are details of Biogen Idec Inc.'s approach to using an iffy but promising method of weeding out likely PML cases from multiple sclerosis patients.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription